Accueil   Agenda - News   Toutes les news SynapCell and Motac Neuroscience Discover New Biomarker of Parkinson’s Disease Progression

SynapCell and Motac Neuroscience Discover New Biomarker of Parkinson’s Disease Progression

Biomarker for Prodromal Disease Will Enable Industry to Assess Neuroprotective and Disease-Modifying Drugs

 

Chicago, IL -- Oct 21, 2019 -- SynapCell and Motac Neuroscience have discovered a new biomarker for progression of Parkinson’s Disease (PD). The BetaPark [evo] enables unprecedented opportunities for drug developers to test the neuroprotective or disease-modifying effects of their compounds. This discovery, combining Motac’s disease modeling and SynapCell’s EEG phenotyping capabilities, is being presented in a poster today in the Circuit Mechanisms of Motor Dysfunction in Parkinson's Disease Session (382.08/F23) of the Society for Neuroscience Annual Meeting in Chicago.

 

Lire le communiqué de presse